Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity.


Journal

Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041

Informations de publication

Date de publication:
12 2020
Historique:
received: 15 07 2020
accepted: 27 08 2020
revised: 26 08 2020
pubmed: 15 9 2020
medline: 22 9 2021
entrez: 14 9 2020
Statut: ppublish

Résumé

Paragangliomas/pheochromocytomas are rare neuroendocrine tumors that arise from the adrenal gland or ganglia at various sites throughout the body. They display a remarkable diversity of driver alterations and are associated with germline mutations in up to 40% of the cases. Comprehensive molecular profiling of abdomino-thoracic paragangliomas revealed four molecularly defined and clinically relevant subtypes. Paragangliomas of the cauda equina region are considered to belong to one of the defined molecular subtypes, but a systematic molecular analysis has not yet been performed. In this study, we analyzed genome-wide DNA methylation profiles of 57 cauda equina paragangliomas and show that these tumors are epigenetically distinct from non-spinal paragangliomas and other tumors. In contrast to paragangliomas of other sites, chromosomal imbalances are widely lacking in cauda equina paragangliomas. Furthermore, RNA and DNA exome sequencing revealed that frequent genetic alterations found in non-spinal paragangliomas-including the prognostically relevant SDH mutations-are absent in cauda equina paragangliomas. Histologically, cauda equina paragangliomas show frequently gangliocytic differentiation and strong immunoreactivity to pan-cytokeratin and cytokeratin 18, which is not common in paragangliomas of other sites. None of our cases had a familial paraganglioma syndrome. Tumors rarely recurred (9%) or presented with multiple lesions within the spinal compartment (7%), but did not metastasize outside the CNS. In summary, we show that cauda equina paragangliomas represent a distinct, sporadic tumor entity defined by a unique clinical and morpho-molecular profile.

Identifiants

pubmed: 32926213
doi: 10.1007/s00401-020-02218-7
pii: 10.1007/s00401-020-02218-7
pmc: PMC7666289
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

893-906

Références

Clin Neuropathol. 2010 Jul-Aug;29(4):227-32
pubmed: 20569673
Histopathology. 1992 Nov;21(5):479-81
pubmed: 1280616
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
J Hypertens. 2008 Jul;26(7):1395-401
pubmed: 18551016
Histopathology. 2017 Sep;71(3):475-479
pubmed: 28374498
Cancer Cell. 2013 Jun 10;23(6):739-52
pubmed: 23707781
Endocr Rev. 2017 Dec 1;38(6):489-515
pubmed: 28938417
Acta Neuropathol. 2019 Nov;138(5):827-835
pubmed: 31278449
Mod Pathol. 2013 Oct;26(10):1365-70
pubmed: 23599157
Cell Tissue Res. 2018 May;372(2):347-365
pubmed: 29362886
Oncogene. 2001 Aug 16;20(36):5084-6
pubmed: 11526495
Histopathology. 1997 Aug;31(2):167-73
pubmed: 9279569
Acta Neuropathol. 2018 Aug;136(2):315-326
pubmed: 29428974
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
Acta Neuropathol. 2016 Jun;131(6):877-87
pubmed: 26857854
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
Cancer. 1986 Oct 15;58(8):1720-35
pubmed: 2875784
Development. 2002 Dec;129(24):5731-41
pubmed: 12421712
J Neurosurg. 1995 Jul;83(1):166-9
pubmed: 7782837
PLoS One. 2018 May 1;13(5):e0196588
pubmed: 29715310
Genet Med. 2018 Dec;20(12):1644-1651
pubmed: 29740169
Acta Neurochir (Wien). 1996;138(4):475-9
pubmed: 8738400
Neurosurg Rev. 2000 Sep;23(3):119-29; discussion 130-1
pubmed: 11086735
Acta Neurochir (Wien). 2006 Jan;148(1):63-6; discussion 66
pubmed: 16283104
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
J Med Genet. 2020 Feb;57(2):96-103
pubmed: 31492822
Hum Pathol. 2020 Sep;103:72-82
pubmed: 32668278
Acta Neuropathol. 2020 Aug;140(2):237-239
pubmed: 32476062
Clin Neuropathol. 1999 Jul-Aug;18(4):208-13
pubmed: 10442464
Bioinformatics. 2013 Oct 15;29(20):2539-46
pubmed: 23956304
Endocr Relat Cancer. 2012 Apr 10;19(2):149-55
pubmed: 22241717
Cancer Cell. 2017 Feb 13;31(2):181-193
pubmed: 28162975
Nat Genet. 2014 Jul;46(7):666-8
pubmed: 24859338
N Engl J Med. 2019 Aug 8;381(6):552-565
pubmed: 31390501
J Neurooncol. 2003 Nov;65(2):177-90
pubmed: 14686739
Bioinformatics. 2012 Dec 15;28(24):3232-9
pubmed: 23093608
PLoS One. 2016 Dec 1;11(12):e0167417
pubmed: 27907167

Auteurs

Leonille Schweizer (L)

Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany. leonille.schweizer@charite.de.
German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany. leonille.schweizer@charite.de.

Felix Thierfelder (F)

Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Christian Thomas (C)

Institute of Neuropathology, University Hospital Münster, Pottkamp 2, Münster, Germany.

Patrick Soschinski (P)

Institute of Neuropathology, University Hospital Münster, Pottkamp 2, Münster, Germany.

Abigail Suwala (A)

Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.

Damian Stichel (D)

Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.

Annika K Wefers (AK)

Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.

Lars Wessels (L)

Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Martin Misch (M)

Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Hee-Yeong Kim (HY)

Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Ruben Jödicke (R)

Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Daniel Teichmann (D)

Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.

David Kaul (D)

Department of Radiation Oncology and Radiotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.

Johannes Kahn (J)

Department of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany.

Michael Bockmayr (M)

Department of Pathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin, Germany.
Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Research Institute Children's Cancer Center Hamburg, Hamburg, Germany.

Martin Hasselblatt (M)

Institute of Neuropathology, University Hospital Münster, Pottkamp 2, Münster, Germany.

Alexander Younsi (A)

Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.

Andreas Unterberg (A)

Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.

Bettina Knie (B)

Department of Neurosurgery, Vivantes Klinikum Im Friedrichshain, Berlin, Germany.

Jan Walter (J)

Department of Neurosurgery, Universitätsklinikum Jena, Jena, Germany.

Diaa Al Safatli (D)

Department of Neurosurgery, Universitätsklinikum Jena, Jena, Germany.

Sven-Axel May (SA)

Department of Neurosurgery, Klinikum Chemnitz, Chemnitz, Germany.

Andreas Jödicke (A)

Department of Neurosurgery, Vivantes Klinikum Neukölln, Berlin, Germany.

Georgios Ntoulias (G)

Department of Neurosurgery, Vivantes Klinikum Neukölln, Berlin, Germany.

Dag Moskopp (D)

Department of Neurosurgery, Vivantes Klinikum Im Friedrichshain, Berlin, Germany.

Peter Vajkoczy (P)

Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Frank L Heppner (FL)

Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Cluster of Excellence, NeuroCure, Charitéplatz 1, 10117, Berlin, Germany.
German Center for Neurodegenerative Diseases (DZNE) Berlin, 10117, Berlin, Germany.

David Capper (D)

Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Wolfgang Hartmann (W)

Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.

Christian Hartmann (C)

Department of Neuropathology, Institute of Pathology, Hannover Medical School, Hannover, Germany.

Andreas von Deimling (A)

Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.

David E Reuss (DE)

Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.

Anne Schöler (A)

Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Arend Koch (A)

Department of Neuropathology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH